D BioTherapeutics, LLC

Salt Lake City, UT · Biotech · Private

DBT178, an oral D-peptide therapeutic that blocks TNFα for inflammatory bowel disease treatment

Grants
$897K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · An oral TNFα inhibitor for inflammatory bowel disease$299,981
Federal grantDepartment of Health and Human Services · Phase I · A Next-Generation Therapeutic for Treatment of TNFα-mediated Inflammatory Diseases$301,488
Federal grantDepartment of Health and Human Services · Phase I · A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis$295,894
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2065PNEUMOTACTIX, LLC——
2066VIRVIO, INC.——
2067Bespoke, Inc.—$14M
2068D BioTherapeutics, LLC——
2069Isomorphic Labs——
2070Courier Therapeutics Inc——
2071UNLOCKED LABS INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.